BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...
这家德国生物科技公司第四季度每股收益达到€1.08,超过分析师预期。营收为€11.9亿,高于€11.2亿的市场预期。 2024财年,BioNTech录得净亏损€6.653亿,即每股亏损€2.77,而2023年同期为净利润€9.303亿,每股收益€3.83。全年营收从上年的€38.2亿下降至€27.5亿。
周一,Jefferies重申了对BioNTech SE(NASDAQ:BNTX)的股票评级和目标价,维持买入评级,目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示,公司收入约为11.9亿欧元,略高于市场预期的11.8亿欧元。得益于运营支出的降低,每股收益(EPS)达到1.08欧元,同样超过了市场预期的0.77欧元。根据 InvestingPro ...
In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...
In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果